Cadrenal Therapeutics, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVKD research report →
Companywww.cadrenal.com
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.
- CEO
- Quang X. Pham
- IPO
- 2023
- Employees
- 4
- HQ
- Ponte Vedra, FL, US
Price Chart
Valuation
- Market Cap
- $14.80M
- P/E
- -1.05
- P/S
- 0.00
- P/B
- 6.91
- EV/EBITDA
- -1.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -411.02%
- ROIC
- -670.38%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-13,237,362 · -24.28%
- EPS
- $-6.64 · 23.94%
- Op Income
- $-13,461,177
- FCF YoY
- -71.12%
Performance & Tape
- 52W High
- $15.99
- 52W Low
- $4.21
- 50D MA
- $5.65
- 200D MA
- $9.26
- Beta
- 1.83
- Avg Volume
- 57.45K
Get TickerSpark's AI analysis on CVKD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 25 | Szot Matthew K | sell | 9,933 |
| Dec 2, 25 | Golden Lee Scott | other | 5,000 |
| Nov 24, 25 | Golden Lee Scott | other | 0 |
| Oct 24, 25 | Szot Matthew K | sell | 1,800 |
| Oct 27, 25 | Szot Matthew K | sell | 1,800 |
| Oct 24, 25 | Pham Quang X | sell | 1,129 |
| Oct 27, 25 | Pham Quang X | sell | 1,315 |
| Oct 9, 25 | Szot Matthew K | sell | 1,693 |
| Oct 13, 25 | Szot Matthew K | sell | 1,800 |
| Oct 9, 25 | Pham Quang X | sell | 1,800 |
Our CVKD Coverage
We haven't published any research on CVKD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CVKD Report →